Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis (NCT02309385) | Clinical Trial Compass
CompletedPhase 1/2
Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis
United States44 participantsStarted 2014-10
Plain-language summary
The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Non-infectious anterior uveitis
Exclusion Criteria:
* lntraocular pressure \> 25mm Hg OU.
* Previous occurrence of an acute episode of anterior uveitis in affected eye(s) within 4 weeks prior to Visit 1.
* Historical or active intermediate or posterior uveitis in affected eye(s).
* Clear systemic causes of uveitis that may require or have required systemic treatment
* Uveitis suspected to have resulted from recent surgery or trauma.
* Use of ocular medication of any kind in affected eye(s) more than 2 days prior to Visit 1, excluding artificial tears, topical allergy medications, eyelid scrubs.
* Current use, or anticipated initiation during the study, of a corticosteroid or an immunosuppressant agent by any route (oral, inhaled, ocular, dermal). Current stable use is allowed.
What they're measuring
1
Proportion of patients with anterior chamber cell ACC grade of zero